Healthcare Providers and Services
Company Overview of Seattle Children's Hospital
Seattle Children's Hospital operates as child health care and pediatric center in the United States. It offers adolescent gynecology, medicine, behavioral, and substance abuse programs; and ambulatory infusion, anesthesia, audiology, bioethics consultation, blood disorders, cancer, cardiac surgery, children with special needs, complex care, craniofacial center, critical care medicine, dental medicine, dialysis, eating disorders, endocrinology/diabetes, family advisory council, financial counseling, and gastroenterology services. The company also provides thoracic surgery, genetics, growth and feeding dynamics, gynecology, health information management, hematology, insurance and interpreter, ...
4800 Sand Point Way NE
Seattle, WA 98105
Founded in 1907
Key Executives for Seattle Children's Hospital
Chief Financial Officer and Senior Vice President
Surgeon-In-Chief, Senior Vice President, President of Cumg and Trustee
President of Seattle Children's Hospital Research Institute
Compensation as of Fiscal Year 2015.
Seattle Children's Hospital Key Developments
Seattle Children's Hospital Announces Executive Changes
Jul 15 15
Seattle Children's announced that Madlyn Murrey, RN, MN, has been appointed to the position of senior vice president and chief nursing officer of Seattle Children's Hospital effective Aug. 24. Murrey will replace Susan Heath, who is retiring later this year. Murrey, 56, currently serves as vice president and chief administration officer of Randall Children's Hospital at Legacy Emanuel in Portland, Ore.
Seattle Children's Hospital Collaborates with NextGxDx, Inc. to Develop a Joint Genetic Test Utilization Management
Jun 25 15
Seattle Children's Hospital announced that it will collaborate with NextGxDx Inc. to develop a joint genetic test utilization management (UM) solution for children's hospitals and pediatric practices. The collaboration will combine the hospital's PLUGS UM program and its team of genetic testing experts with NextGxDx's GeneConnect platform, a technology solution designed to bring highly specialized data and tools to help curb rising genetic testing send-out costs. The collaboration was announced at the first annual PLUGS Summit Utilization Management Conference. PLUGS, which stands for Pediatric Laboratory Utilization Guidance Services, helps clinical laboratories and practitioners decrease costs and errors associated with unnecessary laboratory testing by providing practical resources, expert advice and a valuable peer network for members to develop sustainable utilization management programs.
Kineta, Inc. and Seattle Children's Hospital Announces ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus
Jun 17 15
The Alliance for Children’s Therapeutics, a pediatric research collaboration between Seattle Children’s Research Institute and Kineta Inc. marked its first year anniversary with an encouraging status report on early research efforts using Kineta’s lead drug dalazatide, formerly ShK-186, for children and teens with lupus nephritis. In particular, effector memory T cells have been associated with development of other autoimmune diseases such as psoriasis and rheumatoid arthritis and seem to play a predominant role in causing lupus nephritis. T cells secrete inflammatory mediators (cytokines) that cause tissue damage and inflammation. T cells and B cells make antibodies, which can amplify inflammatory responses. These effector memory T cells depend on a potassium channel called Kv1.3 to function; dalazatide, a first-in-class peptide blocker specifically targets this channel. Preliminary data from the ACT collaboration also suggests that dalazatide is able to selectively block the ability of effector memory T cells to produce inflammatory cytokines implicated in disease. Ongoing ACT research seeks to expand these observations to a greater number of patient samples and test for the target of dalazatide in kidney biopsies. Future work will focus on measuring other parameters of T cell function and the evaluation of their immunomodulation by dalazatide, as well as analysis of Kv1.3 expression in the kidney cells of lupus patients. This work will serve as the foundation for the rationale to evaluate dalazatide in a proof of concept clinical trial for patients with lupus nephritis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|